

Polycystic Kidney Disease Drugs Market Expand CAGR of ~7%, Driving Factors, Size, Revenue & Opportunities 2023-2033

The global polycystic kidney disease drugs market is expected to reach an estimated value of ~USD 732 Million by 2033, by expanding at a CAGR of ~7%.



NEW YORK, NEW YORK, UNITED

STATES, January 23, 2023 /EINPresswire.com/ -- Global Polycystic Kidney Disease Drugs Market Key Insights

During the forecast period of 2023-2033, the global polycystic kidney disease drugs market is expected to reach an estimated value of ~USD 732 Million by 2033, by expanding at a CAGR of ~7%. The market further generated a revenue of ~USD 451 Million in the year 2022. Major key factors propelling the growth of polycystic kidney disease drugs market worldwide are the increasing number of drugs approved by regulatory authorities and a rise in chronic kidney disease incidence.

Market Definition of Polycystic Kidney Disease Drugs

As a result of polycystic kidney disease (PKD), cysts grow excessively in the kidney, ultimately causing kidney failure. By filling the kidneys with fluid, cysts enlarge them and impair their ability to remove waste from the blood. It is also possible for PKD to result in end-stage renal disease as a result of chronic kidney disease. Despite being a common disease, polycystic kidney disease has varying degrees of severity among individuals – even within the same family. PKD typically causes end-stage kidney disease between the ages of 55 and 65. Some individuals with PKD, however, may have a mild form of the disease and not develop an advanced stage of the disease.

Get a sample copy of the report- <https://www.researchnester.com/sample-request-4323>

Global Polycystic Kidney Disease Drugs Market: Growth Drivers

The growth of the global polycystic kidney disease drugs market can majorly be attributed to the increase in the prevalence of autosomal dominant polycystic kidney disease (ADPKD). According

to the World Health Organization, approximately 200,000 to 500,000 people suffer from ADPKD in the United States. However, only about 25 percent of the general public is aware of the disease. Despite its rarity, ADPKD has a significant impact on chronic kidney disease and kidney failure. A significant increase in chronic kidney disease is attributed to polycystic kidney disease, the most common chronic kidney disease. In addition, the increasing number of clinical trials being conducted by major key manufacturers in order to provide patients with the best possible treatment for PKD is expected to drive the market growth over the forecast period. For instance, in July 2022, as part of the Pharmacokinetics Bridging Study Part 1 of the XORTX Therapeutics Inc XRX-OXY-101 Clinical Trial, two versions of the formulation were found to be more bioavailable for oral administration than a control formulation in advance of the ADPKD's late-stage phase 3 registration trial.

The global polycystic kidney diseased rugs market is also estimated to grow majorly on account of the following:

- Increasing personal disposable income
 - Improved healthcare infrastructure
 - Growing spending on healthcare and Medicare facilities
 - Increasing awareness of PKDs through growing initiatives
 - Intensification of research and development
- Global Polycystic Kidney Disease Drugs Market: Restraining Factor

Chronic kidney disease is unaddressed, which is predicted to hinder the market's growth. If chronic kidney disease (CKD) is detected earlier, the progression of the disease can be slowed, complications can be avoided, and cardiovascular-related outcomes may be reduced. Hence this factor is expected to be the major hindrance for the growth of the global polycystic kidney diseased rugs market during the forecast period.

Know More About the Complete Study @ <https://www.researchnester.com/reports/polycystic-kidney-disease-drugs-market/4323>

Global Polycystic Kidney Disease Drugs Market Segmentation

By Type{Autosomal Dominant Polycystic Kidney Disease (ADPKD),Autosomal Recessive Polycystic Kidney Disease (ARPKD), and Others}

The autosomal dominant polycystic kidney disease segment, amongst all the other segments, is anticipated to garner the largest revenue by the end of 2033. The growth of the segment can be attributed to the growing number of autosomal dominant polycystic kidney diseases are being diagnosed around the world. According to our research, ADPKD affects approximately 1 in 500 to 1,000 people in the general population. The number of new cases in the United States each year is about 5,900. There are various clinical and drug development triad being performed for early treatment of ADPKD which is further anticipated to augment segment growth over the forecast period.

By Treatment (Medication, Surgery, and Others)
By Diagnosis (Ultrasound, CT scan, and MRI Scan)
By End User (Hospitals, Specialty Clinics, and Others)
By Region

The North America polycystic kidney diseased rugs market is anticipated to hold the largest market share by the end of 2033 among the market in all the other regions backed by the rise in per capita income in the region along with an increase in awareness of kidney disease early detection. According to the World Bank, the average annual income of every individual in the United States increased by USD 69287.5 in 2021 from USD 63027.7 in 2020. Additionally, the government's commitment to affordable health care, the drug research and development industry's expansion, and the accessibility of drugs are other factors expected to drive the regional market growth over the forecast period.

The market research report on global polycystic kidney diseased rugs also includes the market size, market revenue, Y-o-Y growth, and key player analysis applicable for the market in North America (U.S., and Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), and Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa).

Download Sample Copy of Report @ <https://www.researchnester.com/sample-request-4323>

Key Market Players Featured in the Global Polycystic Kidney Disease Drugs Market

Some of the key players of the global polycystic kidney diseased rugs market are Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., Celgene Corp, XORTX Pharma Corp., ManRos Therapeutics, Palladio Biosciences, Regulus Therapeutics, Inc., Kadmon Holdings, Inc., Reata Pharmaceuticals, Inc., PanoTherapeutics, Inc., and others.

About Research Nester

Research Nester, which is a leading service provider for strategic market research and consulting services, aims to provide unbiased, unparalleled market insights and industry analysis. These analyses help conglomerates, executives, and industries to take wise decisions for their businesses as well as for their future marketing strategy, expansion and investment among others. We believe that our expertise in the field of market research can help businesses to expand to its new horizon. Our team of research analysts can provide businesses a right guidance at the right time, while our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

AJ Daniel

Research Nester Inc.

+1 6465869123

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/612833936>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.